PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 140 filers reported holding PUMA BIOTECHNOLOGY INC in Q1 2017. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $74,556,000 | -17.4% | 1,095,612 | +19.9% | 2.88% | -26.7% |
| Q4 2017 | $90,307,000 | -16.8% | 913,573 | +0.8% | 3.93% | -26.7% |
| Q3 2017 | $108,570,000 | +44.4% | 906,642 | +5.4% | 5.36% | +17.0% |
| Q2 2017 | $75,204,000 | +17.2% | 860,456 | -50.1% | 4.58% | +9.9% |
| Q1 2017 | $64,185,000 | +62.1% | 1,725,414 | +33.7% | 4.17% | +22.0% |
| Q4 2016 | $39,607,000 | -10.8% | 1,290,140 | +94.8% | 3.41% | -3.3% |
| Q3 2016 | $44,406,000 | +149.9% | 662,286 | +605.6% | 3.53% | +82.6% |
| Q4 2014 | $17,766,000 | +45.9% | 93,865 | +84.0% | 1.93% | +37.6% |
| Q3 2014 | $12,173,000 | -32.1% | 51,025 | -70.4% | 1.41% | -34.3% |
| Q1 2014 | $17,922,000 | -25.0% | 172,092 | -25.4% | 2.14% | -27.4% |
| Q4 2013 | $23,882,000 | +30.8% | 230,673 | -32.2% | 2.95% | +7.2% |
| Q3 2013 | $18,253,000 | -23.8% | 340,165 | -37.0% | 2.75% | -34.9% |
| Q2 2013 | $23,960,000 | +34.0% | 539,994 | +0.9% | 4.22% | +28.6% |
| Q1 2013 | $17,878,000 | – | 535,428 | – | 3.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,792,114 | $5,108,000 | 2.15% |
| Camber Capital Management LP | 4,235,000 | $12,070,000 | 0.52% |
| Kynam Capital Management, LP | 579,915 | $1,653,000 | 0.42% |
| GLOBEFLEX CAPITAL L P | 419,322 | $1,195,000 | 0.29% |
| Eversept Partners, LP | 1,435,077 | $4,089,969 | 0.29% |
| ARMISTICE CAPITAL, LLC | 1,500,000 | $4,275,000 | 0.08% |
| RICE HALL JAMES & ASSOCIATES, LLC | 506,066 | $1,442,000 | 0.07% |
| XTX Topco Ltd | 36,130 | $103,000 | 0.04% |
| State of Wyoming | 20,732 | $59,000 | 0.04% |
| Patriot Financial Group Insurance Agency, LLC | 55,500 | $158,000 | 0.03% |